The New Frontier of Immuno-Oncology

Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity.

About Pionyr Immunotherapeutics

The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering, or “tuning”, the myeloid infiltrate of the tumor microenvironment with high specificity and for very specific purposes.

Learn More

Our Science

Pionyr’s Myeloid TuningTM technology builds on the discovery that altering the tumor microenvironment to favor immune-activating cells over immune-suppressing cells enhances the body’s ability to combat cancer.

Learn More

Pionyr Pipeline

Pionyr has a deep and diversified pipeline of myeloid targeting monoclonal antibody therapeutics. The PY314 and PY159 programs, targeting TREM2 and TREM1 respectively, are currently in Phase 1 clinical trials. Pionyr has also completed IND-enabling studies for a third program, PY265, which targets MARCO.

Program (Target)
PY314 (TREM2) / Depletion
PY159 (TREM1) / Repolarization
PY265 (MARCO) / Immune Activation
TME Targeting

Become a Pionyr

Pionyr Immunotherapeutics is currently seeking individuals with myeloid biology, immunology, assay development, in vivo pharmacology, DMPK, or translational science expertise to help advance our lead programs into clinical testing.

Learn More

Contact Us

Pionyr Immunotherapeutics Inc.
2 Tower Pl, Suite 800
South San Francisco, CA 94080
(650) 825-6140